Granted Patent B2

US 12,240,870 · App. 16/971,801 · Granted Mar 4, 2025

Inventors: Richard Messmann (Brighton, MI); Christopher Paul Leamon (West Lafayette, IN); Haiyan Chu (West Lafayette, IN); Yingjuan June Lu (West Lafayette, IN); Philip Stewart Low (West Lafayette, IN); Michael C. Jensen (Bainbridge Island, WA); James Matthaei (Seattle, WA); Navin Robert Charles Pinto (Seattle, WA); Julie Ruggieri Park (Seattle, WA)

Assignees: Purdue Research Foundation; Endocyte, Inc; Seattle Children's Hospital

A61K47/551A61K39/4611A61K39/4631A61K39/464404A61K39/4646A61P35/00C07K14/705A61K2239/38

Abstract

Claims (19)

1. A method of treating a patient for cancer, the method comprising

i) administering to the patient at least one dose of a chimeric antigen receptor T cell (CAR T cell) composition comprising CAR T cells comprising a chimeric antigen receptor (CAR) directed to a targeting moiety; and

ii) administering to the patient a compound, or a pharmaceutically acceptable salt thereof, wherein the compound comprises a small molecule ligand linked to the targeting moiety by a linker, wherein the small molecule ligand is folate and wherein the targeting moiety is fluorescein, or a pharmaceutically acceptable salt thereof, fluorescein isothiocyanate (FITC), or NHS-fluorescein, and wherein the compound, or the pharmaceutically acceptable salt thereof, is administered in at least a first dose escalation sequence and a second dose escalation sequence, wherein a full dose of the compound, or the pharmaceutically acceptable salt thereof, is 10 μg/kg to 50 μg/kg of the compound, or the pharmaceutically acceptable salt thereof;

wherein the first dose escalation sequence for the compound, or the pharmaceutically acceptable salt thereof, comprises administering 3 separate escalating doses up to the full dose of the compound on three separate days in a first two-week cycle; and

wherein the second dose escalation sequence for the compound, or the pharmaceutically acceptable salt thereof, comprises administering 3 separate escalating doses up to the full dose of the compound on three separate days in a second two-week cycle,

whereupon the patient is treated for cancer, and wherein the patient is a human.

2. The method of claim 1 wherein the compound, or the pharmaceutically acceptable salt thereof, is administered in at least a first dose escalation sequence, a second dose escalation sequence, and a third dose escalation sequence.

3. The method of claim 1 wherein a first dose of the CAR T cells and a second dose of the CAR T cells are administered to the patient.

4. The method of claim 3 wherein the first dose of the CART cells is a test dose to monitor the patient for tolerability to the CAR T cells.

5. The method of claim 4 wherein the second dose of the CAR T cells comprises a higher dose of the CAR T cells than the first dose of the CAR T cells.

6. The method of claim 1 wherein the first dose escalation sequence is followed by a period of time during which the compound, or the pharmaceutically acceptable salt thereof, is not administered.

7. The method of claim 6 wherein the period of time is about 7 days.

8. The method of claim 1 wherein the first dose escalation sequence comprises administering to the patient about 1 percent, about 10 percent, and about 100 percent of a full dose of the compound, or the pharmaceutically acceptable salt thereof, on three separate days.

9. The method of claim 2 wherein the second dose escalation sequence comprises administering to the patient about 1 percent, about 30 percent, and about 300 percent of a full dose of the compound, or the pharmaceutically acceptable salt thereof, on three separate days.

10. The method of claim 2 wherein the third dose escalation sequence comprises administering to the patient about 1 percent, about-50 percent, and about 500 percent of a full dose of the compound, or the pharmaceutically acceptable salt thereof, on three separate days.

11. The method of claim 1 wherein, if no cytokine release syndrome (CRS) or neurotoxicity is observed in the patient during the first dose escalation sequence, the method is advanced to the second dose escalation sequence.

12. The method of claim 1 wherein, if no CRS or neurotoxicity is observed in the patient during the second dose escalation sequence, the method is advanced to the third dose escalation sequence.

13. The method of claim 1 wherein if fever without hypotension is observed in the patient and no neurotoxicity is observed in the patient during any one of the dose escalation sequences, all subsequent doses of the compound, or the pharmaceutically acceptable salt thereof, are administered to the patient at the dose escalation sequence level that caused the fever without hypotension.

14. The method of claim 1 wherein, if serious CRS or neurotoxicity occurs in the patient in any dose escalation sequence, all subsequent doses of the compound, or the pharmaceutically acceptable salt thereof, are administered to the patient at the dose escalation sequence level below the dose escalation sequence level that caused the serious CRS or neurotoxicity in the patient.

Assignments (9)

Continuity (5)

References Cited (400)

Cited By (1)

US 12,570,716